flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 clinical (funded by Novo Nordisk) ADA 24: FLOW Trial: Kidney

They are now racing to develop their own pills for obesity and diabetes

This precision-wellness approach helps set realistic expectations, optimize tolerability, and identify candidates most likely to benefit from initial lower-dose strategies or extended titration schedules

In such cases, weight loss medications can be a helpful addition to a comprehensive weight management plan

It is a powerful tool that works best when paired with intentional nutrition and lifestyle habits

Healing from runners knee depends on how serious the injury is and how well you are able to support your own rehabilitation

Desde el inicio del tratamiento